Pathogenesis and prevention strategy of end-stage liver disease complicated with infection

doi:10.3877/cma.j.issn.1674-1358.2025.01.007

Abstract

Abstract:

End-stage liver disease (ESLD) is the late stage of liver disease caused by various chronic liver diseases, with abnormal liver function.Infection is one of the most common complications in the development of ESLD, which can accelerate the deterioration of the patient’s condition and lead to increased mortality.The pathogenesis of ESLD mainly includes immune deflciency, systemic inflammatory response,impairment of liver synthesis function, alteration of intestinal flora and genetic mutations.Concurrent infection with ESLD is characterized by insidious onset, difflculty in early diagnosis and increased multi-drug resistance rate, the diagnosis and treatment of ESLD still face many challenges.This review discusses the pathogenesis of ESLD with infections and intend to provide new ideas for the prevention and treatment.

Key words: End-stage liver disease, Infection, Immune system, Intestinal flora

Xiwen Yan, Huiyuan Liu. Pathogenesis and prevention strategy of end-stage liver disease complicated with infection[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2025, 19(01): 39-43.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2025.01.007

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2025/V19/I01/39

References 43

［1］	陈韬, 宁琴.终末期肝病合并感染诊治专家共识(2021年版)［J］.中华肝脏病杂志,2022,30(2):147-158.
［2］	石春霞, 郭金龚, 作炯.乙型肝炎病毒相关慢加急性肝衰竭合并感染研究进展［J/CD］.中国肝脏病杂志(电子版),2022,14(3):5-8.
［3］	Wong F, Piano S, Singh V, et al.Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure［J］.J Hepatol,2021,74(2):330-339.
［4］	Fernández J, Prado V, Trebicka J, et al.Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-onchronic liver failure in Europe［J］.J Hepatol,2019,70(3):398-411.
［5］	Fernández J, Acevedo J, Wiest R, et al.Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis［J］.Gut,2018,67(10):1870-1880.
［6］	Albillos A, Martin-Mateos R, Van der Merwe S, et al.Cirrhosisassociated immune dysfunction［J］.Nat Rev Gastroenterol Hepatol,2022,19(2):112-134.
［7］	Balazs I, Stadlbauer V.Circulating neutrophil anti-pathogen dysfunction in cirrhosis［J］.JHEP Rep,2023,5(11):100871.
［8］	Triantafyllou E, Woollard KJ, McPhail M, et al.The role of monocytes and macrophages in acute and acute-on-chronic liver failure［J］.Front Immunol,2018,9:2948.
［9］	Doi H, Iyer TK, Carpenter E, et al.Dysfunctional B-cell activation in cirrhosis resulting from hepatitis C infection associated with disappearance of CD27-positive B-cell population［J］.Hepatology,2012,55(3):709-719.
［10］	Albillos A, Lario M, Álvarez-Mon M.Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance［J］.J Hepatol,2014,61(6):1385-1396.
［11］	Rimola A, Soto R, Bory F, et al.Reticuloendothelial system phagocytic activity in cirrhosis and its relation to bacterial infections and prognosis［J］.Hepatology,1984,4(1):53-58.
［12］	Arroyo V, Angeli P, Moreau R, et al.The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis［J］.J Hepatol, 2021,74(3):670-685.
［13］	Wasmuth HE, Kunz D, Yagmur E, et al.Patients with acute on chronic liver failure display “sepsis-like” immune paralysis［J］.J Hepatol,2005,42(2):195-201.
［14］	Bajaj JS.Alcohol, liver disease and the gut microbiota［J］.Nat Rev Gastroenterol Hepatol,2019,16(4):235-246.
［15］	Gracia-Sancho J, Caparrós E, Fernández-Iglesias A, et al.Role of liver sinusoidal endothelial cells in liver diseases［J］.Nat Rev Gastroenterol Hepatol,2021,18(6):411-431.
［16］	Zhao M, Chu J, Feng S, et al.Immunological mechanisms of inflammatory diseases caused by gut microbiota dysbiosis: A review［J］.Biomed Pharmacother,2023,164:114985.
［17］	Trebicka J, Macnaughtan J, Schnabl B, et al.The microbiota in cirrhosis and its role in hepatic decompensation［J］.J Hepatol,2021,75(Suppl 1):S67-S81.
［18］	Marsik C, Mayr F, Cardona F, et al.Endotoxaemia modulates Toll-like receptors on leucocytes in humans［J］.Br J Haematol,2003,121(4):653-656.
［19］	Bellot P, Francés R, Such J.Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications［J］.Liver Int,2013,33(1):31-39.
［20］	Appenrodt B, Grünhage F, Gentemann MG, et al.Nucleotide-binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis［J］.Hepatology,2010,51(4):1327-1333.
［21］	Senkerikova R, de Mare-Bredemeijer E, Frankova S, et al.Genetic variation in TNFA predicts protection from severe bacterial infections in patients with end-stage liver disease awaiting liver transplantation［J］.J Hepatol,2014,60(4):773-781.
［22］	Nischalke HD, Berger C, Aldenhoff K, et al.Toll-like receptor (TLR)2 promoter and intron 2 polymorphisms are associated with increased risk for spontaneous bacterial peritonitis in liver cirrhosis［J］.J Hepatol,2011,55(5):1010-1016.
［23］	Iqbal H, Mehmood BF, Jones K, et al.Fungal infections in liver cirrhosis［J］.Transl Gastroenterol Hepatol,2024,9:49.
［24］	Fernández J, Piano S, Bartoletti M, et al.Management of bacterial and fungal infections in cirrhosis: The MDRO challenge［J］.J Hepatol,2021,75(Suppl 1):S101-S117.
［25］	Lahmer T, Brandl A, Rasch S, et al.Prevalence and outcome of invasive pulmonary aspergillosis in critically ill patients with liver cirrhosis: an observational study［J］.Sci Rep,2019,9(1):11919.
［26］	Franceschini E, Dolci G, Santoro A, et al.Pneumocystis jirovecii pneumonia in patients with decompensated cirrhosis: a case series［J］.Int J Infect Dis,2023,128:254-256.
［27］	Cheng JH, Yip CW, Jiang YK, et al.Clinical predictors impacting cryptococcal dissemination and poor outcome in patients with cirrhosis［J］.Open Forum Infect Dis,2021,8(7):b296.
［28］	Lebrec D, Thabut D, Oberti F, et al.Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis［J］.Gastroenterology,2010,138(5):1755-1762.
［29］	Jia L, Xue R, Zhu Y, et al.The efflcacy and safety of methylprednisolone in hepatitis B virus-related acute-on-chronic liver failure: a prospective multi-center clinical trial［J］.BMC Med,2020,18(1):383.
［30］	Arab JP, Díaz LA, Baeza N, et al.Identiflcation of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study［J］.J Hepatol,2021,75(5):1026-1033.
［31］	Engelmann C, Berg T.G-CSF treatment in decompensated liver disease: a double-edged sword？［J］.Hepatol Int,2022,16(5):979-982.
［32］	De A, Kumari S, Singh A, et al.Multiple cycles of granulocyte colony-stimulating factor increase survival times of patients with Decompensated cirrhosis in a randomized trial［J］.Clin Gastroenterol Hepatol,2021,19(2):375-383.
［33］	丁胜楠, 杜娜, 杨伟民, 等.肝硬化失代偿期患者细菌感染及治疗现状: 第三届全国病毒性肝炎慢性化重症化基础与临床研究进展学术会议［C］.中国重庆,2013.
［34］	Garcia-Martinez R, Caraceni P, Bernardi M, et al.Albumin:pathophysiologic basis of its role in the treatment of cirrhosis and its complications［J］.Hepatology,2013,58(5):1836-1846.
［35］	Peng D, Xing HY, Li C, et al.The clinical efflcacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir Monotherapy in HBV-related cirrhosis: a systematic review and meta-analysis［J］.BMC Gastroenterol,2020,20(1):348.
［36］	Bernardi M, Angeli P, Claria J, et al.Albumin in decompensated cirrhosis:new concepts and perspectives［J］.Gut,2020,69(6):1127-1138.
［37］	Wang X, Sun R, Wei H, et al.High-mobility group box 1 (HMGB1)-Toll-like receptor (TLR)4-interleukin (IL)-23-IL-17A axis in druginduced damage-associated lethal hepatitis: Interaction of γδ T cells with macrophages［J］.Hepatology,2013,57(1):373-384.
［38］	Rice TW, Wheeler AP, Bernard GR, et al.A randomized, doubleblind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis［J］.Crit Care Med,2010,38(8):1685-1694.
［39］	陈竹, 曾义岚, 王丽, 等.乙型肝炎肝硬化并自发性细菌性腹膜炎的病原学及耐药性分析［J/CD］.中华实验和临床感染病杂志(电子版),2018,12(6):553-558.
［40］	Yang W, Guo G, Sun C.Therapeutic potential of rifaximin in liver diseases［J］.Biomed Pharmacother,2024,178:117283.
［41］	Patel VC, Lee S, McPhail M, et al.Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy:RIFSYS randomised controlled trial［J］.J Hepatol,2022,76(2):332-342.
［42］	Ansaldo E, Farley TK, Belkaid Y.Control of immunity by the microbiota［J］.Annu Rev Immunol,2021,39:449-479.
［43］	Shah YR, Ali H, Tiwari A, et al.Role of fecal microbiota transplant in management of hepatic encephalopathy: Current trends and future directions［J］.World J Hepatol,2024,16(1):17-32.

[1]	Yunjie Nong, Xiaogui Huang, Yulan Huang, Hengrong Nong. Clinical value of ultrasound in diagnosis of multiple microbial pulmonary infections [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2024, 21(09): 872-876.
[2]	Medical Quality Control Center for Infectious Diseases National. Expert consensus on quality improvement of human immunodeficiency virus infection diagnosis and treatment [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2025, 19(01): 1-8.
[3]	Wangziyan Lu, Yan Wang, Yuanxing Wu. Research progress of vascular graft infection [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2025, 19(01): 34-38.
[4]	Xiangqi Liu, Ying Chen, Jiashun Wu, Xueting Luo, Xin Yang, Shijun Kuang. Evaluation of nitroimidazole antibiotics in the prevention of postoperative infection following the extraction of bone embedded mandibular third molar：A prospective randomized clinical trial [J]. Chinese Journal of Stomatological Research(Electronic Edition), 2025, 19(02): 112-118.
[5]	Dong Xiang, Xiaohua Wang, Peihang Xu, Chunrong Ju. Donor-derived cell-free DNA in the diagnosis of postoperative lung transplantation complications [J]. Chinese Journal of Transplantation(Electronic Edition), 2025, 19(01): 37-42.
[6]	of Organ Transplantation of Chinese Medical Association Branch, of Organ Transplant Physicians of Chinese Medical Doctor Association Branch, of Kidney Transplantation, China International Exchange and Promotive Association for Medical and Health Care Branch. Clinical diagnosis and treatment guideline for invasive aspergillosis in kidney transplant recipients in China [J]. Chinese Journal of Transplantation(Electronic Edition), 2024, 18(06): 321-333.
[7]	Yuanzhi Chen, Xia Cai. Application of reusable inventory counting cards and charts in the management of endoscopic instrument management in disinfection supply center [J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(02): 174-180.
[8]	Shuang Chen, Enmin Huang. Indicators related to the quality management of hernia and abdominal wall surgery [J]. Chinese Journal of Hernia and Abdominal Wall Surgery(Electronic Edition), 2025, 19(01): 18-20.
[9]	Benlei Zhu, Fuheng Liu, Taicheng Zhou, Shuang Chen, Bing Zeng, Wenchang Gan, Shaoyong Peng, Yingru Li. Exploration of surgical approach for removing infected meshes after groin hernia surgery [J]. Chinese Journal of Hernia and Abdominal Wall Surgery(Electronic Edition), 2025, 19(01): 63-68.
[10]	Yingyu Chen, Xueni Liu, Mei Wu, Tingting Zhao, Yongfei Liu. Clinical value of eosinophilic to neutrophilic ratio in patients with acute exacerbation of chronic obstructive pulmonary disease in intensive care [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2025, 18(01): 48-54.
[11]	of Organ Transplantation of Chinese Medical Association Branch. Chinese practice guidelines for diagnosis and treatment of ischemic-type biliary lesion after liver transplantation [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 739-748.
[12]	Peipei Chen, Shiming Li, Zening Wang, Qiang Fu. Diagnosis and treatment experience of secondary local infections after frontal sinus management in craniotomy surgery [J]. Chinese Journal of Neurotraumatic Surgery(Electronic Edition), 2025, 11(01): 52-56.
[13]	Baojing Du, Minye Li, Yunxia Wang, Yongjing Shen, Weiwei Tan. Relationship between intestinal flora characteristics and serum zinc, CK-MB and inflammatory factors in children with rotavirus infection-related diarrhea [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2025, 15(01): 78-82.
[14]	Lingling Jia, Fei Teng, Jian Chang, Fu Huang, Jianping Liu. Progress in application of cardiopulmonary rehabilitation in various diseases [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(09): 859-862.
[15]	Yao Deng, Bicheng Xie, Bian Wu, Danfeng Lan. Research progress on the effect of bariatric surgery on intestinal flora and metabolic inflammatory syndrome [J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2025, 11(01): 70-75.

Please choose a citation manager

Content to export